首页> 外文期刊>Oncogene >Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours
【24h】

Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours

机译:睾丸肿瘤中RASSF1A抑癌基因的频繁表观遗传失活以及精原细胞瘤和非精原细胞睾丸生殖细胞肿瘤的甲基化特征

获取原文
           

摘要

Testicular germ cell tumours (TGCTs) are histologically heterogeneous neoplasms with variable malignant potential. Previously, we demonstrated frequent 3p allele loss in TGCTs, and recently we and others have shown that the 3p21.3 RASSF1A tumour suppressor gene (TSG) is frequently inactivated by promoter hypermethylation in a wide range of cancers including lung, breast, kidney and neuroblastoma. In order to investigate the role of epigenetic events in the pathogenesis of TGCTs, we analysed the promoter methylation status of RASSF1A and nine other genes that may be epigenetically inactivated in cancer (p16INK4A, APC, MGMT, GSTP1, DAPK, CDH1, CDH13, RAR and FHIT) in 24 primary TGCTs (28 histologically distinct components). RASSF1A methylation was detected in four of 10 (40%) seminomas and 15 of 18 (83%) nonseminoma TGCT (NSTGCT) components (P=0.0346). None of the other nine candidate genes were methylated in seminomas, but MGMT (44%), APC (29%) and FHIT (29%) were frequently methylated in NSTGCTs. Furthermore, in two mixed germ cell tumours, the NSTGCT component for one demonstrated RASSF1A, APC and CDH13 promoter methylation, but the seminoma component was unmethylated for all genes analysed. In the second mixed germ cell tumour, the NSTGCT component was methylated for RASSF1A and MGMT, while the seminoma component was methylated only for RASSF1A. In all, 61% NSTGCT components but no seminoma samples demonstrated promoter methylation at two or more genes (P=0.0016). These findings are consistent with a multistep model for TGCT pathogenesis in which RASSF1A methylation occurs early in tumorigenesis and additional epigenetic events characterize progression from seminoma to NSTGCTs.
机译:睾丸生殖细胞肿瘤(TGCT)是具有不同恶性潜能的组织学异质性肿瘤。以前,我们在TGCT中证明了频繁的3p等位基因缺失,最近我们和其他人已经证明,启动子的高甲基化作用常常使3p21.3 RASSF1A肿瘤抑制基因(TSG)在包括肺癌,乳腺癌,肾癌和神经母细胞瘤在内的多种癌症中失活。 。为了研究表观遗传事件在TGCT发病机理中的作用,我们分析了RASSF1A和其他9种可能在癌症中被表观遗传失活的基因的启动子甲基化状态(p16INK4A,APC,MGMT,GSTP1,DAPK,CDH1,CDH13,RAR和FHIT)在24个主要TGCT中(28个组织学上不同的成分)。在10个(40%)的精原细胞瘤中有四个检测到RASSF1A甲基化,在18个(83%)的非精原细胞TGCT(NSTGCT)组分中检测到15个(P = 0.0346)。其他9个候选基因在精原细胞瘤中均未甲基化,但MGMT(44%),APC(29%)和FHIT(29%)在NSTGCT中经常甲基化。此外,在两种混合的生殖细胞肿瘤中,一种的NSTGCT组分显示RASSF1A,APC和CDH13启动子甲基化,但对于分析的所有基因,精原细胞组分均未甲基化。在第二个混合生殖细胞肿瘤中,NSTGCT成分被RASSF1A和MGMT甲基化,而精原细胞成分仅被RASSF1A甲基化。总共有61%的NSTGCT成分,但没有精原细胞瘤样品在两个或多个基因上显示启动子甲基化(P = 0.0016)。这些发现与TGCT发病机制的多步骤模型一致,在该模型中,RASSF1A甲基化发生在肿瘤发生的早期,其他表观遗传事件则表征了从精原细胞瘤向NSTGCT的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号